Eledon Presents New Long-Term Data Of Tegoprubart From Phase 2 Kidney Transplant Study; Stock Down

Eledon Pharmaceuticals reported positive long-term data from its Phase 2 BESTOW program evaluating Tegoprubart versus tacrolimus in kidney transplant patients. The update is encouraging for the company’s lead transplant asset and supports the clinical-stage pipeline, but the article provides no detailed efficacy or safety metrics. The news is likely supportive for the stock, though the broader market impact should be limited.

Analysis

Eledon Pharmaceuticals reported positive long-term data from its Phase 2 BESTOW program evaluating Tegoprubart versus tacrolimus in kidney transplant patients. The update is encouraging for the company’s lead transplant asset and supports the clinical-stage pipeline, but the article provides no detailed efficacy or safety metrics. The news is likely supportive for the stock, though the broader market impact should be limited.